Member Directory
Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded by the inventors of the Cellular Thermal Shift Assay (CETSA®) to both develop the method and to provide a commercial service for organisations wanting to use the method.. . CETSA measures compound binding under actual physiological conditions within either a cellular of lysate environment. The assay relies on a well-established observation that compound binding with a protein will change its thermal denaturation point, meaning that at a given denaturation temperature there will be a difference in the abundance of the intact protein as compared with a negative control. It is the only technique that will confirm such target engagement is occurring and provides ‘real world’ EC50 values for your compound in cells.. . The company controls the patents on CETSA and delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects.
Our award-winning life sciences team is led by highly-ranked lawyers who advise companies in the biotech, pharmaceutical, diagnostics, veterinary and healthcare sectors. We add value with lawyers who understand the science from their degree subjects, and understand your business, having worked in-house for life science companies, or with them for many years. We act for companies, at all stages of their life cycle, including global pharmaceutical companies, larger plcs and SMEs, together with research organisations, venture capital funds and universities. 'Impressive IP practice acting for life sciences businesses, universities and their spinoffs… Recommended for licence and research agreements.' - Chambers 2017.
Pharma International provides global pharmaceutical regulatory consultancy services, with an emphasis on the emerging markets. Fully licensed by Swissmedic, Pharma International is authorised to trade in biotechnology, pharmaceuticals and medical devices internationally – as well as providing Swiss Qualified Person services. Seminars on regulatory affairs, especially Asia including ASEAN, China, Korea and India, are conducted regularly and can be adapted to in-house requirements.
A company dedicated to:. Training (Explaining how the biopharmaceutical industry operates). Science communication:(Enhancing the verbal presentation skills of young scientists). Coaching: (Preparing non specialists for business interactions with technical clients). Consultancy: (Harnessing knowledge of the biomedical and drug discovery scene accumulated. over many years)
Regulatory Consultancy
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 15,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, visit: https://www.pharmaron.com
PharmaVentures is a specialist healthcare consultancy which delivers practical and cost-effective solutions to clients world-wide in the pharmaceutical, biotechnology, healthcare, finance & related service sectors.. . . . Strategy, Analysis, Evaluation. Expert Reports, Due Diligence, Deal Benchmarking, Structuring & Negotiation, Product Partner Identification
PhoreMost™ is focused on bringing more effective and affordable targeted medicines to patients. To achieve this aim, PhoreMost is developing a next-generation phenotypic screening technology that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the company's proprietary Protein Interference (PROTEINi®) technology, PhoreMost has developed SITESEEKER®; a platform that can systematically unmask cryptic druggable sites in the human genome and then link them to useful therapeutic functions in a live-cell context.